These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37925103)

  • 21. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
    Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
    Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
    Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
    Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Risk Prediction Flowchart of Vancomycin-Induced Acute Kidney Injury to Use When Starting Vancomycin Administration: A Multicenter Retrospective Study.
    Miyai T; Imai S; Kashiwagi H; Sato Y; Kadomura S; Yoshida K; Yoshimura E; Teraya T; Tsujimoto T; Kawamoto Y; Itoh T; Ueno H; Goto Y; Takekuma Y; Sugawara M
    Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33352848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of a risk prediction model of vancomycin-associated nephrotoxicity to be used at the time of initial therapeutic drug monitoring: A data mining analysis using a decision tree model.
    Imai S; Yamada T; Kasashi K; Niinuma Y; Kobayashi M; Iseki K
    J Eval Clin Pract; 2019 Feb; 25(1):163-170. PubMed ID: 30280456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.
    Tsutsuura M; Moriyama H; Kojima N; Mizukami Y; Tashiro S; Osa S; Enoki Y; Taguchi K; Oda K; Fujii S; Takahashi Y; Hamada Y; Kimura T; Takesue Y; Matsumoto K
    BMC Infect Dis; 2021 Feb; 21(1):153. PubMed ID: 33549035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
    Neely MN; Kato L; Youn G; Kraler L; Bayard D; van Guilder M; Schumitzky A; Yamada W; Jones B; Minejima E
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients.
    Kanazawa N; Shigemi A; Amadatsu N; Arimura K; Shimono S; Oda K; Chuang VTG; Matsumoto K; Kawamura H; Terazono H
    J Infect Chemother; 2024 Apr; 30(4):323-328. PubMed ID: 37940038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
    Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
    Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
    Zhang Y; Wang T; Zhang D; You H; Dong Y; Liu Y; Du Q; Sun D; Zhang T; Dong Y
    Ther Drug Monit; 2020 Aug; 42(4):600-609. PubMed ID: 32097248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections.
    Clark L; Skrupky LP; Servais R; Brummitt CF; Dilworth TJ
    Ther Drug Monit; 2019 Aug; 41(4):483-488. PubMed ID: 30817704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].
    Xue S; Lu H; Tang L; Fang J; Shi L; Li J; Yu Y; Zhou Q; Xue S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):50-55. PubMed ID: 32148231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of Bayesian Area Under the Concentration-Time Curve-Based Pharmacokinetic Dosing Based on a One-Compartment Model and Trough-Only Monitoring for Vancomycin.
    Salehpour N; Riley LD; Gonzales MJ; Kobic E; Nix DE
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0017223. PubMed ID: 37133362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
    Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin.
    Lee BV; Fong G; Bolaris M; Neely M; Minejima E; Kang A; Lee G; Gong CL
    Clin Microbiol Infect; 2021 Sep; 27(9):1346.e1-1346.e7. PubMed ID: 33221430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: A simulation study.
    Oda K; Yamada T; Matsumoto K; Hanai Y; Ueda T; Samura M; Shigemi A; Jono H; Saito H; Kimura T
    Clin Transl Sci; 2023 Nov; 16(11):2265-2275. PubMed ID: 37718491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized dosing of vancomycin in geriatric patients.
    Suchánková H; Lečbychová K; Strojil J; Fürst T
    Epidemiol Mikrobiol Imunol; 2020; 69(4):172-180. PubMed ID: 33445941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Area-Under-Curve-Guided Versus Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-Analysis.
    Lim AS; Foo SHW; Benjamin Seng JJ; Magdeline Ng TT; Chng HT; Han Z
    Ther Drug Monit; 2023 Aug; 45(4):519-532. PubMed ID: 36728329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.